Back to results
US 12,686,722 B2Granted
Anti-HVEM antibodies and use thereof
Assignees4C Biomed Limited, Tel HaShomer Medical Research Infrastructure and Services Ltd.
InventorsEyal Greenberg, Gilli Galore-Haskel, Efrat Merhavi-Shoham, Gal Markel, Jacob Schachter
Life of this patent
Estimating the term…
Abstract
Agents that bind HVEM, inhibit HVEM-BTLA interaction and activate downstream HVEM signaling are provided. Methods of treating disease with those agents and kits comprising those agents are also provided.
Claims14
An antibody or antigen binding fragment thereof comprises three heavy chain CDRs (CDR-H) and three light chain CDRs (CDR-L), wherein:
- CDR-H1 comprises the amino acid sequence set forth in SEQ ID NO:
- 1 (SYAMS), CDR-H2 comprises the amino acid sequence as set forth in SEQ ID NO:
- 2 (AISGSGGSTYYADSVKG), CDR-H3 comprises the amino acid sequence as set forth in SEQ ID NO:
- 3 (APGDYTAYFDY), CDR-L1 comprises the amino acid sequence as set forth in SEQ ID NO:
- 4 (RASQSVSSYLA), CDR-L2 comprises the amino acid sequence as set forth in SEQ ID NO:
- 5 (GASSRAT), and CDR-L3 comprises the amino acid sequence as set forth in SEQ ID NO:
- 6 (QQYGSSPPYT).
4 more elements
Dependencies are inferred from the claim text.